Navigation Links
New Studies Show Popular Heartburn Medications Moderate the Effect of Taking Widely Prescribed Heart Drug
Date:5/6/2009

o address a related issue that has raised questions about the PPI/clopidogrel interaction, the researchers also looked at whether or not PPIs independently increase the risk of a CV event. The results of this study found that there was no independent effect from taking a PPI in the absence of clopidogrel. The study included 1,641 patients who had undergone a stent procedure but were not taking clopidogrel and compared CV event hospitalizations of patients on a PPI to those not taking a PPI. These findings were recently presented at the American Heart Association's Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular and Stroke (QCOR).

"Our study, along with a 2007 FDA review and other researchers' work, provides strong evidence that PPIs do not independently raise cardiovascular risks for stent patients and further strengthens the observation that this interaction exists between PPIs and clopidogrel and impairs the effectiveness of the antiplatelet drug," said Epstein. "Given the totality of the evidence generated on this interaction and the known benefits of clopidogrel in reducing the risk of death, heart attack and stroke after coronary stenting, patients and their physicians should continue to trust in the use of this medication and consider a PPI only when clearly indicated."

About Medco

Medco Health Solutions, Inc (NYSE: MHS) is a leading health care company, serving the needs of more than 60 million people. Medco, the world's most advanced pharmacy(R), provides clinically driven pharmacy services designed to improve the quality of care and lower total health care costs for private and public employers, health plans, labor unions and government agencies of all sizes, and for individuals served by Medicare Part D Prescription Drug Plans. Through its unique Medco Therapeutic Res
'/>"/>

SOURCE Medco Health Solutions, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. New Studies on Once-Daily Extended Release Pramipexole Presented at American Academy of Neurology Annual Meeting
2. Affitech-Discovered Anti-PS Antibodies in Development by Peregrine Pharmaceuticals Show Excellent Functionality in Preclinical Studies
3. Studies Presented at AACR Annual Meeting Highlight Multiple Immunomodulatory Mechanisms of Peregrines PS-Targeting Antibodies
4. Pharmasset Voluntarily Halts Clinical Studies with Clevudine in Hepatitis B Infected Patients
5. Alimera Sciences Iluvien(TM) Phase 3 Studies for DME Pass Final DSMB Review Prior to October Readout
6. Cynosure Announces Presentation of Favorable Results from Post-Marketing Studies of Smartlipo MPX
7. Cardium Reports on Applicability of Corgentin to Stem Cell Therapies: Independent Studies Indicate that Ad5IGF-1 Potentiates Stem Cells to Improve Cardiac Function After Heart Attack
8. Avineuro Pharmaceuticals, Inc. Announces Beginning of Phase I Clinical Studies of AVN-211, Potent Small Molecule for Treatment of Schizophrenia.
9. Studies Show Combination Laser Therapy Effective At Clearing Acne, Reducing Oil Production
10. Prescient Medical Achieves Milestones in Clinical Studies of vProtect(TM) Luminal Shield
11. Intellect Neurosciences, Inc. Announces Independent Studies on Copper Binding Properties of its Lead Candidate OXIGON(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... Conn. , May 17, 2013 /PRNewswire-iReach/ -- ... and recombinant proteins, is placing renewed emphasis on ... the rise as a number of factors are ... for pharmaceutical makers and their delivery device partners ... previously refractory conditions, the growing trend toward self-administration ...
(Date:5/17/2013)... May 17, 2013  Boehringer Ingelheim will contribute ... at the American Thoracic Society International Conference (ATS ... May 17 – 22. Data will ... the treatment of chronic obstructive pulmonary disease (COPD) ... as investigational compounds for asthma, idiopathic pulmonary fibrosis ...
(Date:5/17/2013)... 2013  Sanofi (EURONEXT: SAN and NYSE: SNY ... JAKARTA , examining the selective JAK2 inhibitor SAR302503 ... dose groups. The primary endpoint assessed the proportion of ... data reported in previous trials, the most common adverse ... will be presented at an upcoming medical congress. ...
Breaking Medicine Technology:Pharmaceutical Makers and Delivery Device Partners Rethink Delivery Technologies - New Report Examines this Evolving Segment 2Pharmaceutical Makers and Delivery Device Partners Rethink Delivery Technologies - New Report Examines this Evolving Segment 3Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 2Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 3Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 4Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 5Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 6Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 7Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 8Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 2Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 3Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 4Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 5Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 6
... 12, 2011 Unilife Corporation ("Unilife" or the "Company") ... the development of its AutoInfusor™ portfolio of subcutaneous infusion ... 5mL, 7mL, and 10mL volumes. Unilife has ... of pharmaceutical and biotechnology companies with drugs that have ...
... one of the largest distributors of high-performance and engineering-grade ... new EVONIK VESTAKEEP® 5000 PEEK extruded stock shapes. ... most ductility of any PEEK material available in extruded ... Marketing at Modern Plastics. EVONIK VESTAKEEP® ...
Cached Medicine Technology:Unilife Develops Proprietary Portfolio of Wearable Subcutaneous Infusion Devices for the Self-Administration of Large Volume Drugs by Patients 2Unilife Develops Proprietary Portfolio of Wearable Subcutaneous Infusion Devices for the Self-Administration of Large Volume Drugs by Patients 3Unilife Develops Proprietary Portfolio of Wearable Subcutaneous Infusion Devices for the Self-Administration of Large Volume Drugs by Patients 4
(Date:5/18/2013)... of coffee is associated with a reduced risk ... disease, Mayo Clinic research shows. The findings were ... conference in Orlando, Fla. , PSC is ... results in inflammation and subsequent fibrosis that can ... and biliary cancer. , "While rare, PSC has ...
(Date:5/18/2013)... (PRWEB) May 18, 2013 Today, ... insurance agents’ role in Marketplaces . Zane ... traditional employer sponsored health benefits, is the leader ... and health reimbursement arrangements . , According ... and Human Services (HHS) recently released a much-anticipated ...
(Date:5/18/2013)... 18, 2013 The “World Healthcare IT ... studies the major market drivers, restraints, and opportunities in ... , Browse , 89 market ... TOC on "Healthcare IT Market" , ... on reports. , The global healthcare IT market is ...
(Date:5/18/2013)... As metal-on-metal hip implant ... Bernstein Liebhard LLP notes that a new study has ... damage before they experience any pain from a hip. ... will appear in the Journal of Bone & Joint ... of their hips. The researchers found tissue damage ...
(Date:5/18/2013)... (PRWEB) May 18, 2013 The “Sleep ... Pulse Oximeters, CPAP, Masks, Adaptive Servo-Ventilation (ASV), Oral Appliances, ... Forecast to 2017” analyzes and studies the major market ... and Rest of the World. , Browse , ... 16 Figures , 318 ...
Breaking Medicine News(10 mins):Health News:Zane Benefits Publishes New Information on Insurance Agents’ Role in Marketplaces 2Health News:Zane Benefits Publishes New Information on Insurance Agents’ Role in Marketplaces 3Health News:Zane Benefits Publishes New Information on Insurance Agents’ Role in Marketplaces 4Health News:Healthcare IT Market to reach US$ 162.2 Billion by 2015 at a CAGR of 10.2% - New Report by MarketandMarkets 2Health News:Healthcare IT Market to reach US$ 162.2 Billion by 2015 at a CAGR of 10.2% - New Report by MarketandMarkets 3Health News:Metal-on-Metal Hip Implants: Bernstein Liebhard LLP Comments on New Study Finding that Tissue Damage Precedes Pain in Metal-on-Metal Hip Replacement Patients 2Health News:Metal-on-Metal Hip Implants: Bernstein Liebhard LLP Comments on New Study Finding that Tissue Damage Precedes Pain in Metal-on-Metal Hip Replacement Patients 3Health News:Metal-on-Metal Hip Implants: Bernstein Liebhard LLP Comments on New Study Finding that Tissue Damage Precedes Pain in Metal-on-Metal Hip Replacement Patients 4Health News:Sleep Apnea Devices Market to reach $19.72 Billion by 2017 - New Report by MarketandMarkets 2Health News:Sleep Apnea Devices Market to reach $19.72 Billion by 2017 - New Report by MarketandMarkets 3
... A new US research has found that young women are ... young men.The study, which contradicts the stereotype that men// are ... The Annals of Internal Medicine this week. ,Researchers from ... years after they were discharged from hospital after a heart ...
... new treatment for people with severe cases of multiple sclerosis, ... stem cells// from the patients’ blood, killing the cells that ... the healthy cells back to the body. The hope is ... system cells and the disease process can be stopped. ...
... humans and animals, the nerve cells must communicate with the ... a new study, biologists from Utah showed how a single ... to send these chemical signals. , The experimented ... the Scientists crippled the protein UNC-13. , " All ...
... technique for prostate cancers has been found out by researchers.// ... traditional exam for prostate cancer, the doctor takes six tissue ... University, researchers said that it is better to take more ... extended sector biopsy. They took 12 samples - ...
... The research involves a drug called zoledronic acid, which is ... in which calcium seeps from the bones. The drug was ... bone density, and the effect persisted for at least a ... the blood.// ,It will be about five years before ...
... drug Clarinex is coming on the market with an ... allergy drugs. "Billions of seasonal allergies, one tiny blue ... makes Claritin, the nation's best-selling prescription allergy drug. In ... switch Claritin to over-the-counter drug. A month's supply, which ...
Cached Medicine News:
... Our original design and available ... It does not have the wings ... much easier to remove. This is ... an inexpensive method to print a ...
... Volks drive to provide ... to bring you a lens ... in a non-contact slit lamp ... true 3D viewing of the ...
... writes and prints "Smart" labels. As well ... barcode on the label surface. SATO's industrial ... range of applications, including: Compliance Labeling, Warehouse ... Retail Labeling, Product Authentication. CL408e RFID and ...
... Gallery is a unique label design ... on an easy-to-use and intuitive user ... Label Gallery offers a family of ... multi-lingual user interface and complete barcode ...
Medicine Products: